Marc Better

A biotechnology professional with more than 25 years of experience in cell therapy and biologics CMC. Dr. Better led process and analytical development, process characterization and process validation efforts resulting in the successful U.S. licensure of Yescarta, a first in class anti-CD19 CAR T cell therapy. SVP Product Sciences (process development & manufacturing) at Kite Pharma, Inc. Executive Director, Process Science at Boehringer Ingelheim. Executive Director, Process Development at Amgen.